🔗 Share this article

While the US undertakes historic adjustments to its immunization guidelines, an unexpected name has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning Covid vaccinations during the global health crisis and has concentrated on possible deaths after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Schedule

Agency leaders had intended to announce sweeping changes to the childhood vaccination calendar recently, bringing the US with Denmark’s national calendar, it is understood – a major change that would put the US out of step with much of the global community with insufficient data for public health gain. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood vaccine recommendations in the US so as to align more in line with the Danish model, a nation with comprehensive healthcare and a population roughly the size of Wisconsin’s.

In her initial statements, she has kept her attention on vaccination policy – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no apparent experience in drug development, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who ran the center have had.”

This division has an enormous workload at the FDA, the former commissioner stated.

“The public just pays attention on the new drug program, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and every single one must be looked after,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major management element to the role, which oversees more than 5,000 staff members. “It’s a huge leadership role, if you do it right,” she said.

Official Statement and Disputed Initiatives

When asked about questions about Høeg’s credentials and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “questions rely on incorrect presumptions”.

“This background is consistent with the responsibilities of her job,” the official stated, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a controversial expedited medication authorization process that apparently troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the calls?” Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the agency appears to be shifting towards less stringent oversight of all drugs, with the exception of immunizations.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, past, Howard observe. She published a analysis using non-validated crowd-sourced reports to determine the frequency of myocarditis following Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Included in her “policy goals” for the new federal leadership included altering guidelines for novel immunizations and halting “optional” vaccines, she remarked post-election on a audio program. At the agency, Høeg has according to sources floated the idea of preventing teenage boys from getting Covid vaccines.

“She is an thorough ideologue who commences with her preconceived notions and tailors the evidence to fit the evidence in a highly misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|